SCHEMBL5877823

SCHEMBL5877823

Cc1ccc(S(=O)(=O)n2nc(Nc3ccccc3)c3c2CC(c2ccccc2)(c2ccccn2)C=C3)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
GRM4 Q14833 2/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 3/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
CYP2C19 P33261 1/20 0.32
HSD11B1 P28845 1/20 0.32
GAA P10253 3/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
IKBKB O14920 1/20 0.31
CHUK O15111 1/20 0.31
METAP1 P53582 1/20 0.30
SLC9A1 P19634 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876035 0.96 NR1H2 (0.35) NR1H2NR1H3GRM4ALDH1A1KDM4E
SCHEMBL5875996 0.91 NR1H2 (0.38) NR1H2NR1H3ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5877420 0.91 NR1H2 (0.32) NR1H2NR1H3CYP2C19GAAMEN1
SCHEMBL5877764 0.89 NR1H2 (0.35) NR1H2NR1H3ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5876223 0.88 SMN1; SMN2 (0.33) NR1H2NR1H3GRM4ALDH1A1KDM4E
SCHEMBL5876253 0.88 NR1H2 (0.35) NR1H2NR1H3ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5877113 0.87 GBA1 (0.34) NR1H2NR1H3CYP2C19GAAMEN1
SCHEMBL5878049 0.87 SMN1; SMN2 (0.34) NR1H2NR1H3ALDH1A1KDM4EPOLB
SCHEMBL5876722 0.86 POLB (0.35) NR1H2NR1H3ALDH1A1POLBSMN1; SMN2
SCHEMBL5877005 0.86 NR1H2 (0.33) NR1H2NR1H3ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT NR1H2 556/4885NR1H3 456/4885GRM4 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.